There is now a growing consensus that hormones and neurotransmitters, in stimulating or inhibiting cellular function, produce their characteristic changes by utilizing a relatively small number of general receptor transduction systems. One such mechanism, which was initially conceived to have as its end-point, the elevation in cytosolic free Ca*+, is the inositol lipid signalling system. This activation process is now known, in addition, to lead to the activation of protein kinase C, and there is a large body of evidence indicating that the synergistic action of Ca'+ and protein kinase C plays a central role in controlling cell function (for a recent review see Downes & Michell, 1985) . Despite the enormous advances that this decade has brought in our understanding of the mechanisms by which receptor agonists increase the cytosolic free Ca2+ concentration and activate cellular protein kinases, our ability to perturb these processes pharmacologically, other than at the level of the receptor itself, has remained somewhat primitive. The ready availability of specific pharmacological research tools would do much to speed our understanding both of the extent to which the signalling system pervades general cell function, and of the detailed control processes which govern the performance of the inositol lipid cycle under conditions of both short-and long-term receptor stimulation. Also, at a time when the long-held notion that second messenger systems are too ubiquitous to be plausible drug targets is receiving at least a partial come-uppance with the advent of tissue-selective cyclic nucleotide phosphodiesterase inhibitors, it does not seem too fanciful to advance the hope that the inositol lipid cycle and its sequelae might similarily yield potentially valuable therapeutic agents. I t is from this perspective that the present short review is written.
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One of the few agents that interferes with the inositol lipid cycle in any selective sense is lithium. This agent, in the form of lithium carbonate, has been used for over a quarter of a century in the treatment of manic-depressive illness. Its utility is proven (Schou, 1976) , but its mode of action remains a matter of conjecture. Throughout the 1970s, Allison and his colleagues conducted an investigation into the interaction of lithium with inositol metabolism, primarily in the central nervous system (CNS). The brain of animals receiving lithium (and with plasma lithium levels in the therapeutic range (0.5-1 .O mmol/l), shows a marked decrease in inositol and an increase in inositol monophosphate levels (Allison & Stewart, 1971; Allison et al., 1976) . The molecular basis for these changes, which are dependent on tonic muscarinic action within the CNS (they are not observed after blockade of muscarinic receptors and are markedly enhanced by cholinesterase inhibitors such as physostigmine; Allison et al., 1976) , was subsequently shown to be the ability of lithium to block the enzyme inositol I-monophosphatase (Hallcher & Sherman, 1980) . Thus, during muscarinic receptor-stimulated inositol lipid metabolism, in the case of the CNS, the formation of Ins1 P is indirectly increased due to the agonist-activated hydrolysis of PIPz to Ins( 1,4,5)P, and 1,2-diacylglycerol (DAG) (Fig. I) . The presumed major route of catabolism of Ins( 1 . 4 3 P, to inositol yields, at its penultimate step, Ins1 P, and its hydrolysis, as is shown in Fig. I , is inhibited by lithium.
Since the formation of the important messenger substances produced by the inositol lipid metabolism, DAG and Ins(1,4,5)P3, is several steps distant from the main point at which lithium blocks the cycle, it is not immediately evident how, and under what circumstances, the cation might influence signal transduction. In 1982, Berridge vt al. discussed this question, and suggested a working hypothesis by which the anti-manic actions of lithium might, nevertheless, derive from its ability to block inositol phosphate catabolism. In the theory, the importance lies not in the accumulation of InslP, but in the depletion of inositol. Cells can obtain inositol from two sources: from the circulating plasma and by synthesis de n o w from glucose. The latter route involves, as an intermediate step, the formation of InslP and its dephosphorylation to inositol; as a consequence, the synthesis of inositol can be blocked by lithium. When radiolabelled inositol is injected intravenously, only vanishingly small amounts of radioactivity reach the CNS (Spector & Lorenzo, 1975) , and it is widely believed that the bulk of CNS inositol is derived from synthesis de novo within the CNS (Margolis et al., 1971) . This contrasts markedly with peripheral tissues which, provided they can accumulate the sugar from the plasma, can obtain pre-formed inositol. The CNS, therefore, should be particularly sensitive to this action of lithium; a feature which coincides nicely with the therapeutic findings where, by comparison with the CNS, the peripheral actions of lithium are limited (Schou, 1976) . Since, within the CNS, both the normal turnover of the inositol lipid cycle and the synthesis of the inositol dc novo will result in its entrapment as InslP, the demand on the cellular free inositol pool will be immense. The problem will be particularly acute in cells with a high basal turnover of the inositol-containing lipids, i.e. during tonic receptor stimulation. Thus, Berridge et al. (1982) proposed that cells which are downstream from a hypothetical group of pathologically active neurons responsible for the manic state, might be expected to experience hyperstimulation and. as a consequence, rather rapidly become depleted of cellular free inositol. In turn, this deprivation would lead to a run-down in cellular inositol lipids to the extent that these cells might become less sensitive to neuronal information transmitted via the inositol lipid signalling pathway. Clinically, this 
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Abbreviations: PA, phosphatidic acid; Ins(cl:2) P, inositol 1,2-cyclic phosphate: Ins(cl:2-4) P:. inositol I ,2-cyclic 4-bisphosphate; Ins(cl :2-4,5)P7, inositol 1,2-cyclic 4,5-trisphosphate. Note that the existence of the pathway forming the inositol cyclic phosphates is uncertain at the present time.
would be a beneficial outcome, since the aberrant stimuli would have less influence on higher processes such as behaviour.
This elegant theory, formulated at a time when our understanding of the inositol lipid signalling pathway was much less advanced than a t present, has never been seriously tested. The aim of the present report will be to discuss how the more recent advances in inositol lipid biochemistry affect the hypothesis, to examine the features which might contribute to tissue or cell specificity in this action of lithium and to indicate how the theory might be tested.
Lithium stintulates the accumulation of' multiple inositol pkosphates in ctd1.s
Although the early biochemistry indicated that lnsl P would be the likely substance accumulating in the presence of lithium, recent work suggests that this is a vast oversimplification. Many reports indicate that, in the presence of lithium, there is enhanced accumulation of InsP, and InsP,, in addition to InsP, (Drummond et al.. 1984; Thomas ~t al., 1984) . This finding, which appears to be particularly prominent when higher concentrations of lithium are used (Thomas 1'1 al., 1984) , may, as we have argued, be partly indirect, the result of product inhibition of InsP, phosphatase. for example (Drummond r t al., 1984) . However, in the liver, it is evident from broken cell studies that the removal of the 4-phosphate from Ins( 1.4)P, is also blocked by lithium (see Fig. 1 and Storey ct ul., 1984) . In this situation. the metabolism of Ins( l .4)Pz may be redirected via the I-phosphatase yielding Ins4P, a substance whose catabolism. in the liver at least. is insensitive to lithium (Storey (it al., 1984) . Thus, it is conceivable that. in certain tissues. the blockade of inositol phosphate breakdown by lithium may, as a result of this redirection. be incomplete. Whether the reports of the enhanced accumulation of Ins4P in tissues and cells in the presence of lithium (Sherman ct al., 1985; Siess, 1985) reflect a tissue-specific inhibition of its catabolism or merely the fact that inositol 4-phosphatase activity is low in cells remains to be elucidated. These questions are not merely Vol. 15 academic, since a cell's ability to evade the lithium block might render it immune to the effects of the cation.
The enhanced accumulation of InsP, by lithium in stimulated cells (Drummond et ul., 1984; Storey ~t al., 1984) . which is not accompanied by any enhancement in agoniststimulated Ca'+ mobilization (Storey et al., 1984) , can probably be explained by the existence within cells of multiple InsP, isomers (Irvine rt al., 1984 (Irvine rt al., . 1985 . the catabolism of only one of which, Ins(1,3,4)P7, is sensitive to lithium (Burgess r t al., 1985) . Since this isomer is much weaker than Ins( l,4,5)P3 as a Ca'+ -mobilizing agent ( R . F. Irvine, personal communication) , and accumulates relatively slowly by comparison with Ins( I ,4,5)P, (Burgess r t al., 1985; lrvine c t al., 1985) , its accumulation may be redundant in terms of cell signalling, unless it subserves an entirely unrelated function. I t is, therefore, evident that the complement of different inositol phosphates accumulating in lithium-treated cells may be both numerous and tissue-selective: in G H , pituitary cells, for example, h.p.1.c. analysis of inositol phosphates reveals that the accumulation of at least five substances is enhanced by lithium (P. J . Hughes & A. H . Drummond, unpublished work) . In many cases the levels of individual metabolites can increase as much as 3C50-fold and, bearing in mind the example that high concentrations of Ins2P can inhibit the breakdown of Ins1 P (Naccaroto ('I al., 1974) , it seems possible that lithium may lead indirectly to the accumulation of isomers whose catabolism is not directly lithium-sensitive. Whether this is significant in therapeutic terms remains unclear at present.
Control of' c d u l u r lithium und inositol lovcls
Two other considerations that may affect a cell's sensitivity to lithium are its ability to limit lithium uptake into the cytosol (where many of the inositol phosphatases are located) and its ability to concentrate inositol from the plasma. The ability of lithium to substitute for sodium in ion channels. pumps and exchangers is by n o means universal; it is not transported by the N a + C a " exchanger, but is carried by the N a + -H ' exchanger in synaptosomal mem- 10 nM; A, l00nM; A, 1 PM) for the times indicated. the reaction was stopped using 10% (w/v) trichloroacetic acid and samples extracted for ['Hlinositol (after anionexchange chromatography) or total inositol-containing lipids by the method described by Drummond rt ul. (1984) . The values shown arc mcans of duplicate determinations in an experiment which was repeated twice with similar results.
branes (Blaustein & Oborn, 1975; Schmalzing et d., 1986) .
It passes readily through Na' channels, but is not a substrate for the Na+/K'-ATPase (Dahl & Hokin, 1974; Landowne et ul., 1975) . Thus, it is conceivable that its accumulated level in different cells may vary considerably depending o n how the cell regulates its cytosolic sodium. Equally important is the size of a cell's free inositol pool and the rate with which it can be replenished from the extracellular medium. The mechanism by which inositol gains entry to a cell appears to vary considerably. Some cells, notably neurons and pituitary cells, exhibit saturable inositol uptake systems and readily concentrate the sugar (Spector, 1976;  A. H. Drummond. unpublished work), a feature which is reflected in the high free inositol content found in these tissues (Dawson & Freinkel. 1961) . Others, such as hepatocytes and parotid acinar cells, appear to accumulate it in a non-saturable manner (Prpic et ul., 1982; Downes & Stone, 1986) . Since there are a number of observations that indicate that only high ( > 1 mM) extracellular inositol concentrations can overcome the inositol-depleting action of lithium (Downes & Stone, 1986; A. H. Drummond, unpublished work) , studies of the mechanisms which control free inositol pools in cells are urgently required. Note that in the presence of lithium, the reaction forming inositol from inositol monophosphate (IP,) is blocked (h); this leads to a diminishing loss of metabolites beyond this point in the cycle and gain in those preceding the step. In ((1). the inositol-requiring step is the formation of PI from CDPdiacylglycerol. This latter substance, however. does not accumulate to any enormous extent. and the bulk of the lipid lost from PI is recovered in DAG and TAG.
Consequences of cellulur inositol run-down
In a number of stimulated cells which have been deprived of extracellular inositol. treatment with lithium leads to a rapid decline in cellular free inositol (Thomas et al., 1984; Drummond & Raeburn, 1984; Downes & Stone, 1986) . The data presented in Fig. 2 . obtained with G H , cells, demonstrate that this can be complete within IOmin of agonist addition. As might be expected, the rate of decline is directly related to the concentration of stimulant applied (Fig. 2) and, indeed, to the level of lithium present (data not shown). The change in inositol precedes a similar fall in cellular inositol-containing lipids (Fig. 2 , lower panel) , although, as we have reported, PIPz levels are much more resistant to this depletion than PIP or, in particular, PI ( Fig. 3 and Drummond & Raeburn, 1984) . Or some significance is the finding that a proportion of the glycerol backbone lost from the depleted inositol lipids accumulates as D A G (Fig. 3 and Drummond & Raeburn, 1984) . While this may. to some extent. be cell-selective (Bocckino ef al., 1985; Downes & 619th MEETING. CAMBRIDGE Stone, 1986) . it is possible that enhancement of agoniststimulated DAG levels may lead to inappropriate activation of protein kinase C. The consequences of this are difficult to gauge at present since protein kinase C can apparently subserve positive or negative roles in cell activation (Drummond & Maclntyre. 1985) . but since protein kinase C activation can lead to receptor down-regulation, it is intriguing to speculate that the effects of both lithium and the conventional anti-depressants may derive from a similar ability to regulate receptor number. A less devious result of inositol lipid los:, as proposed by Berridge et al. (1982) , would be a disability in inositol lipid-linked signalling. Indeed, there is evidence to suggest that when GH, cells are depleted of inositol lipids as described above, washed free of the agonist, and then restimulated by thyrotropin-releasing hormone (TRH), the ability of the tripeptide to increase InsP, and cytosolic free Ca2+ levels is impaired (A. H . Drummond & L. A. Joels, unpublished work). I t should be possible, using GH, cells as a model system, to create a situation not unlike that encountered by neurons in the CNS of a lithium-treated animal. The results of such a study should go some way to indicating whether the inositol lipid-related theory of lithium's action in mania has some practical credibility.
